Adverse events associated with smallpox vaccination in the United States, January-October 2003
- PMID: 16333009
- DOI: 10.1001/jama.294.21.2734
Adverse events associated with smallpox vaccination in the United States, January-October 2003
Abstract
Context: On January 24, 2003, the US Department of Health and Human Services (DHHS) implemented a preparedness program in which smallpox (vaccinia) vaccine was administered to federal, state, and local volunteers who might be first responders during a bioterrorism event.
Objective: To describe results from the comprehensive DHHS smallpox vaccine safety monitoring and response system.
Design, setting, and participants: Descriptive study of adverse event reports from the DHHS smallpox vaccine safety monitoring and response system received between January 24 and October 31, 2003, through the Vaccine Adverse Event Reporting System (VAERS) and the Centers for Disease Control and Prevention. A total of 37,901 volunteers in 55 jurisdictions received at least 1 dose of smallpox vaccine.
Main outcome measures: Number of vaccinations administered and description of adverse events and reporting rates.
Results: A total of 38,885 smallpox vaccinations were administered, with a take rate of 92%. VAERS received 822 reports of adverse events following smallpox vaccination (overall reporting rate, 217 per 10,000 vaccinees). A total of 590 adverse events (72%) were reported within 14 days of vaccination. Nonserious adverse events (n = 722) included multiple signs and symptoms of mild and self-limited local reactions. One hundred adverse events (12%) were designated as serious, resulting in 85 hospitalizations, 2 permanent disabilities, 10 life-threatening illnesses, and 3 deaths. Among the serious adverse events, 21 cases were classified as myocarditis and/or pericarditis and 10 as ischemic cardiac events that were not anticipated based on historical data. Two cases of generalized vaccinia and 1 case of postvaccinial encephalitis were detected. No preventable life-threatening adverse reactions, contact transmissions, or adverse reactions that required treatment with vaccinia immune globulin were identified. Serious adverse events were more common among older revaccinees than younger first-time vaccinees.
Conclusions: Rigorous smallpox vaccine safety screening, educational programs, and older vaccinees may have contributed to low rates of preventable life-threatening adverse reactions. Other rare, clinically significant, or unexpected cardiac adverse events were detected by timely review of VAERS data and intensive clinical case investigation.
Comment in
-
Smallpox vaccinations and adverse events.JAMA. 2006 Apr 26;295(16):1897-8. doi: 10.1001/jama.295.16.1897-c. JAMA. 2006. PMID: 16639045 No abstract available.
Similar articles
-
Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions.MMWR Recomm Rep. 2006 Feb 3;55(RR-1):1-16. MMWR Recomm Rep. 2006. PMID: 16456528
-
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2004 Apr;23(4):287-94. doi: 10.1097/00006454-200404000-00002. Pediatr Infect Dis J. 2004. PMID: 15071280 Review.
-
Smallpox vaccine: contraindications, administration, and adverse reactions.Am Fam Physician. 2003 Sep 1;68(5):889-96. Am Fam Physician. 2003. PMID: 13678138 Review.
-
Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 2003 Apr 4;52(RR-7):1-16. MMWR Recomm Rep. 2003. PMID: 12710832
-
Smallpox vaccination and adverse reactions. Guidance for clinicians.MMWR Recomm Rep. 2003 Feb 21;52(RR-4):1-28. MMWR Recomm Rep. 2003. PMID: 12617510
Cited by
-
Biology of Variola Virus.Adv Exp Med Biol. 2024;1451:139-149. doi: 10.1007/978-3-031-57165-7_9. Adv Exp Med Biol. 2024. PMID: 38801576 Review.
-
Construction of a recombinant vaccine expressing Nipah virus glycoprotein using the replicative and highly attenuated vaccinia virus strain LC16m8.PLoS Negl Trop Dis. 2023 Dec 15;17(12):e0011851. doi: 10.1371/journal.pntd.0011851. eCollection 2023 Dec. PLoS Negl Trop Dis. 2023. PMID: 38100536 Free PMC article.
-
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Vaccines (Basel). 2023 Aug 24;11(9):1410. doi: 10.3390/vaccines11091410. Vaccines (Basel). 2023. PMID: 37766090 Free PMC article. Review.
-
mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge.Nat Commun. 2023 Sep 22;14(1):5925. doi: 10.1038/s41467-023-41628-5. Nat Commun. 2023. PMID: 37739969 Free PMC article.
-
Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies.Vaccine. 2023 May 11;41(20):3171-3177. doi: 10.1016/j.vaccine.2023.04.010. Epub 2023 Apr 21. Vaccine. 2023. PMID: 37088603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical